Driehaus Capital Management Reduces $2M in Xenon Pharmaceuticals Inc. ($XENE)
Key Points
- Driehaus Capital Management changed its Xenon Pharmaceuticals Inc. ($XENE) stake by 1.0% last quarter, cutting to 4,491,653 shares worth $234.02 million.
- Wall Street's consensus rating on $XENE is Strong Buy and an average price target of $80.56.
- $XENE last traded around $52.10.
Driehaus Capital Management trimmed its position in Xenon Pharmaceuticals Inc. ($XENE) by 1.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,491,653 shares of Xenon Pharmaceuticals Inc. after selling 47,038 shares during the quarter. Driehaus Capital Management's holdings in Xenon Pharmaceuticals Inc. were worth $234.02 million as of its most recent filing.
Xenon Pharmaceuticals Inc. ($XENE) Stock
Xenon Pharmaceuticals Inc. Earnings
Analysts Set New Price Targets
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.